Barrowcliffe Susan E. 4
4 · Aimmune Therapeutics, Inc. · Filed Mar 6, 2018
Insider Transaction Report
Form 4
Barrowcliffe Susan E.
General Manager, Europe
Transactions
- Award
Common Stock, $0.0001 par value
2018-03-04+9,375→ 9,375 total - Award
Stock Option (right to buy)
2018-03-04+56,250→ 56,250 totalExercise: $34.07Exp: 2028-03-04→ Common Stock (56,250 underlying)
Footnotes (2)
- [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F2]The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.